George Lowell - 01 Jan 2023 Form 3/A - Amendment Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role: Director
Signature: /s/ George H. Lowell
Issuer symbol: BVXV
Transactions as of: 01 Jan 2023
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 23 Jan 2023, 07:04:49 UTC
Date Of Original Report: 03 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BVXV	Ordinary Shares						421,680	01 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BVXV	Stock Options (right to buy)							01 Jan 2023	Ordinary Shares	720,000	$0.1990	Direct	F1, F2
holding	BVXV	Stock Options (right to buy)							01 Jan 2023	Ordinary Shares	1,000,000	$0.1740	Direct	F1, F3
holding	BVXV	Restricted Share Units							01 Jan 2023	Ordinary Shares	133,200		Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F2	Stock options were granted on May 28, 2019 and are fully vested.
F3	Stock options were granted on April 6, 2021 and vest on a monthly basis during a period of three years.
F4	Restricted share units were granted on April 6, 2021 and vest on a monthly basis during a period of three years.
F5	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share.